Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
33.70 x 1 39.96 x 6
Post-market by (Cboe BZX)
33.84 -2.37 (-6.55%) 04/01/25 [NASDAQ]
33.70 x 1 39.96 x 6
Post-market 34.14 +0.30 (+0.89%) 19:36 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
33.69
Day High
36.25
Open 36.06
Previous Close 36.21 36.21
Volume 993,200 993,200
Avg Vol 728,970 728,970
Stochastic %K 14.92% 14.92%
Weighted Alpha -38.39 -38.39
5-Day Change -4.85 (-12.54%) -4.85 (-12.54%)
52-Week Range 33.69 - 60.37 33.69 - 60.37
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,349,461
  • Shares Outstanding, K 92,501
  • Annual Sales, $ 560,230 K
  • Annual Income, $ -569,180 K
  • EBIT $ -536 M
  • EBITDA $ -513 M
  • 60-Month Beta 0.67
  • Price/Sales 6.24
  • Price/Cash Flow N/A
  • Price/Book 13.68

Options Overview Details

View History
  • Implied Volatility 57.46% ( +3.30%)
  • Historical Volatility 40.38%
  • IV Percentile 63%
  • IV Rank 29.67%
  • IV High 110.63% on 04/12/24
  • IV Low 35.02% on 06/25/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,139
  • Volume Avg (30-Day) 363
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 23,846
  • Open Int (30-Day) 22,506

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.58
  • Number of Estimates 8
  • High Estimate -1.06
  • Low Estimate -2.14
  • Prior Year -2.03
  • Growth Rate Est. (year over year) +22.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.69 +0.45%
on 04/01/25
Period Open: 42.92
43.22 -21.70%
on 03/03/25
-9.08 (-21.16%)
since 02/28/25
3-Month
33.69 +0.45%
on 04/01/25
Period Open: 42.07
46.50 -27.23%
on 02/06/25
-8.23 (-19.56%)
since 12/31/24
52-Week
33.69 +0.45%
on 04/01/25
Period Open: 46.97
60.37 -43.95%
on 09/16/24
-13.13 (-27.95%)
since 04/01/24

Most Recent Stories

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 33.84 (-6.55%)
Ultragenyx to Participate at Investor Conferences in March

RARE : 33.84 (-6.55%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 33.84 (-6.55%)
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

RARE : 33.84 (-6.55%)
Ultragenyx: Q4 Earnings Snapshot

Ultragenyx: Q4 Earnings Snapshot

RARE : 33.84 (-6.55%)
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

RARE : 33.84 (-6.55%)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

RARE : 33.84 (-6.55%)
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained...

RARE : 33.84 (-6.55%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 33.84 (-6.55%)
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

RARE : 33.84 (-6.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 38.06
2nd Resistance Point 37.15
1st Resistance Point 35.50
Last Price 33.84
1st Support Level 32.94
2nd Support Level 32.03
3rd Support Level 30.38

See More

52-Week High 60.37
Fibonacci 61.8% 50.18
Fibonacci 50% 47.03
Fibonacci 38.2% 43.88
Last Price 33.84
52-Week Low 33.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies